Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab in Systemic Lupus Erythematosus
NCT04963296Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Oct 2021
- Primary completion
- Sep 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of obinutuzumab in systemic lupus erythematosus (SLE), sponsored by Roche. Started Oct 2021; status: active, not recruiting.
02
Drugs
obinutuzumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT04963296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04963296.